C
코미팜
041960KOSDAQ53.0 / 100
Reference Date: 2026-10-23
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Komipharm is a company established in 1972 specializing in the production and sale of animal vaccines and pharmaceuticals, with key products including ASF vaccines and Pro-vacTM PED-Fc. It is actively expanding globally through the development of cancer treatment drug PAX-1. In 2024, sales increased by 38% year-on-year to 58.8 billion won, with operating profit from animal pharmaceuticals reaching 89.77 billion won.
Number of Employees
172people
Average Salary
47.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
9.05Industry Average 1.200.0Point
7.5x industry avg (risky)
ROE
-11.67Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
12.64Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.5% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲65.2% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 0.8% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (49%)
Current 8,740Won52-week high 11,60052-week low 5,890
1-month return1.0Point
1m -10.63% (falling)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0